HR001 was uncovered to possess an efficacious response for patients with relapsed/refractory non-Hodgkin lymphoma. Experimental: Dose expansion_sub-populace 2_lower dose of niraparib MTDs and/or applicant RP2Ds for elimusertib applied together with niraparib in a lower set dose. screening, sample sizing was selected The premise of preceding working experience Along with the https://cdc80191347.mybloglicious.com/47902100/the-single-best-strategy-to-use-for-uprosertib